NASDAQ:IOVA 3 November 2025 - 23 June 2026

Iovance Biotherapeutics, Inc. is back on traders’ radar heading into Dec. 23, 2025, after a sharp move higher to $2.78 at the Dec. 22 close and an early pre-market indication around $2.80. StockAnalysis That bounce matters because Iovance has become the kind of stock where small news can hit like a cymbal crash—and not just because it’s biotech. With short interest around one-third of the float, any new analyst note, operational update, or sentiment shift can amplify price swings. MarketBeat

December 18, 2025 — Iovance Biotherapeutics, Inc. is back in the spotlight after a sharp two-day move that pushed the stock back to the $2.5 area—still far below where many Wall Street price targets sit, but enough to reignite the “is this finally a bottom?” debate around one of biotech’s most volatile commercial launches. According to Investing.com’s recent trading history, IOVA jumped 12% on Wednesday, December 17, closing at $2.52 on 23.27 million shares after already rising on December 16. Investing.com As of December 18, the stock continued to trade around $2.52, with a recent 52-week range of $1.64 to $8.15 and a reported -65.10% change over the past year. Investing.com

Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab, then reinfused to attack cancer. This approach, originally pioneered by NCI’s Dr. Steven Rosenberg in the 1980s, finally reached fruition when Iovance’s lifileucel earned FDA approval in 2024 as the first-ever TIL therapycancer.gov. Lifileucel is indicated for unresectable or metastatic melanoma that has progressed after standard immunotherapiesfda.gov. In clinical trials, lifileucel achieved an objective response rate ~31% in heavily pre-treated melanoma patientsfda.gov, with some complete tumor regressions observed. Notably, many responses have proven durable – about 40% of responders had no cancer progression one year post-infusion in trialscancer.gov – signaling the potential for long-term remission in a subset of patients. How TIL Therapy Works: Similar to CAR T-cell therapy, lifileucel is an autologous T-cell product made from the patient’s own cellscancer.gov. However, TIL therapy differs from CAR-T in key ways: CAR-T cells are collected from blood and genetically engineered to target a specific antigen, whereas TIL cells are harvested directly from the patient’s tumor and are not genetically modifiedcancer.govcancer.gov. Because they come from the tumor microenvironment, these TILs